Physician profile
Woo S Ahn
NPI 1396807806
$5,319.54
in general payments reported to CMS, 2019-2025
22 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $407 · 2021: $568 · 2022: $795 · 2023: $424 · 2024: $793 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,079.51 | 2019-2025 | Creon, Linzess |
| Amgen INC. | $886.22 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $785.53 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $598.82 | 2019-2025 | Ozempic, Rybelsus |
| Aimmune Therapeutics, INC. | $382.87 | 2024-2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $329.38 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.77 | 2019-2024 | Tradjenta, Jardiance |
| Sumitomo Pharma America, INC. | $175.98 | 2024-2025 | Gemtesa |
| Radius Health, INC. | $156.36 | 2022-2024 | Tymlos |
| Pfizer INC. | $105.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.54 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $69.39 | 2020-2021 | |
| Ibsa Pharma INC. | $61.63 | 2021-2022 | |
| Lilly USA, LLC | $59.84 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $56.68 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $47.89 | 2020 | |
| Vivus LLC | $39.68 | 2022-2023 | Pancreaze |
| Allergan, INC. | $28.38 | 2019 | |
| Astellas Pharma US INC | $22.31 | 2019 | |
| Glaxosmithkline, LLC. | $21.88 | 2024 | Arexvy |
| Scilex Pharmaceuticals INC. | $16.50 | 2019 | |
| Eisai INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Woo Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.